Clay Siegall is the CEO of Seattle Genetics that majorly deals with cancer research. He has driven many innovations to advance cancer treatment. The company under his leadership has seen tripling of stock prices for over five years. This is a clear demonstration of the growing role of the company in cancer research.
The CEO is very passionate about making the lives of cancer patients better. Currently, Clay Siegall is serving in various capacities in Seattle Genetics such as president, chairman of the board and as CEO of the company. He has been the CEO since 2002. His two-decade long experience working for the company he co-founded, has enabled him to meet various objectives. The company has realized groundbreaking cancer therapies that benefit patients.
Ever since graduating from the George Washington University with a Ph.D. in Genetics, he has accomplished a lot professionally. Clay Siegall’s career started at the Bristol-Myers Squibb Pharmaceutical Research Institute as a senior research investigator. Dr. Clay was promoted to Principal Scientist position later, and then he moved to National Cancer Institute as a Biotechnology Fellow and Staff Fellow.
These successes helped him make his launch of Seattle Genetics. In his professional achievements, he concentrates on significant cutting-edge and cancer research developments. Clay siegall derives motivation from his need to help ease the suffering of cancer patients. This has enabled him to take the company to the forefront in cancer research.
Under the leadership of Dr. Clay, Seattle Genetics has developed ADCs – the first antibody drug conjugates. It has also produced ADCETRIS, which was approved by FDA in 2011. ADCETRIS is currently expanding globally and is available in at least 60 countries. His influence on the development of the cancer drug is a testament of dedication towards prioritizing cancer therapies for many years.
Clay siegall was integral to the development of ADCETRIS. In addition, he is instrumental in providing good leadership, which has enabled Seattle Genetics to raise at least $1.2 billion in public and private funding for the cancer research. The advancement of cancer treatment under his leadership is with the help of innovative technology. Dr. Clay Siegall represents a unique combination of visionary leadership and scientific acumen.